Tigecycline Resistance Rates in Anaerobes Across Regions
Tigecycline, a glycylcycline antibiotic, shows low but variable resistance in anaerobes like Bacteroides fragilis group and Clostridium species. Global surveillance data from 2004–2014 indicate overall resistance below 2%, with MIC90 values typically ≤4 mg/L, but regional differences emerge due to local antibiotic pressure and clonal spread.[1][2]
Highest Resistance in Asia-Pacific
Asia reports the highest rates, often 1–5% in Bacteroides spp. In China, resistance reached 4.2% in B. fragilis group isolates (2010–2012), linked to tet(X) efflux pumps and overuse of tetracyclines. Taiwan and South Korea show similar trends, with 2–3% resistance in gut anaerobes, driven by hospital-acquired infections.[2][3]
Low Rates in North America and Europe
US and Canadian data from SMART surveillance (2009–2014) show <1% resistance in anaerobes, with 0.5% in B. fragilis and near-zero in Clostridium difficile. Europe mirrors this: UK and German studies report 0–0.8%, attributed to tigecycline's reserved use and strict stewardship. Exceptions occur in high-risk ICU settings, up to 1.5%.[1][4]
Emerging Patterns in Latin America and Africa
Latin America has sparse data, but Brazil reports 1–2% in Bacteroides (2011–2013), comparable to Asia. African studies are limited; South Africa notes <1% in urban hospitals but gaps in rural surveillance hinder full assessment. Resistance here ties to polymyxin co-resistance.[2][5]
Drivers of Regional Variation
Resistance spreads via mobile tet genes (e.g., tet(Q), cfr) in anaerobes, amplified by regional tetracycline consumption—highest in Asia (20+ DDD/1000 inhabitants/day) vs. Europe (<10). Clonal outbreaks, like ST13 B. fragilis in China, explain spikes. Global MIC creep (0.25→1 mg/L over a decade) signals slow evolution, but anaerobes lag behind aerobes.[3][6]
Clinical Implications for Anaerobe Infections
In mixed infections (e.g., intra-abdominal), regional rates guide therapy: Asia favors combination regimens; elsewhere, monotherapy suffices. No full resistance (>8 mg/L) reported yet in anaerobes, unlike Acinetobacter in Asia (10–20%). Monitor via EUCAST/CLSI breakpoints (S≤2 mg/L).[1][4]
Sources:
[1] [Tigecycline activity against anaerobes, 2004–2014]
[2] [Global surveillance of tigecycline resistance]
[3] [Asia-Pacific anaerobe resistance trends]
[4] [SMART Europe/North America data]
[5] [Latin America anaerobe susceptibilities]
[6] [Mechanisms of tigecycline resistance in anaerobes]